<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25686105</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1546-170X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature medicine</Title>
          <ISOAbbreviation>Nat Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.</ArticleTitle>
        <Pagination>
          <StartPage>248</StartPage>
          <EndPage>255</EndPage>
          <MedlinePgn>248-55</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3806</ELocationID>
        <Abstract>
          <AbstractText>The NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disorders such as cryopyrin-associated periodic syndrome (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease and atherosclerosis. We describe the development of MCC950, a potent, selective, small-molecule inhibitor of NLRP3. MCC950 blocked canonical and noncanonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibited activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes. MCC950 reduced interleukin-1β (IL-1β) production in vivo and attenuated the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Furthermore, MCC950 treatment rescued neonatal lethality in a mouse model of CAPS and was active in ex vivo samples from individuals with Muckle-Wells syndrome. MCC950 is thus a potential therapeutic for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases, and a tool for further study of the NLRP3 inflammasome in human health and disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Coll</LastName>
            <ForeName>Rebecca C</ForeName>
            <Initials>RC</Initials>
            <AffiliationInfo>
              <Affiliation>1] School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. [2] Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robertson</LastName>
            <ForeName>Avril A B</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chae</LastName>
            <ForeName>Jae Jin</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Inflammatory Disease Section, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Higgins</LastName>
            <ForeName>Sarah C</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Muñoz-Planillo</LastName>
            <ForeName>Raúl</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Inserra</LastName>
            <ForeName>Marco C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>1] Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia. [2] School of Pharmacy, University of Queensland, Brisbane, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vetter</LastName>
            <ForeName>Irina</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>1] Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia. [2] School of Pharmacy, University of Queensland, Brisbane, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dungan</LastName>
            <ForeName>Lara S</ForeName>
            <Initials>LS</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Monks</LastName>
            <ForeName>Brian G</ForeName>
            <Initials>BG</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Innate Immunity, University Hospital, University of Bonn, Bonn, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stutz</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Innate Immunity, University Hospital, University of Bonn, Bonn, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Croker</LastName>
            <ForeName>Daniel E</ForeName>
            <Initials>DE</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Butler</LastName>
            <ForeName>Mark S</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haneklaus</LastName>
            <ForeName>Moritz</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sutton</LastName>
            <ForeName>Caroline E</ForeName>
            <Initials>CE</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Núñez</LastName>
            <ForeName>Gabriel</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Latz</LastName>
            <ForeName>Eicke</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>1] Institute of Innate Immunity, University Hospital, University of Bonn, Bonn, Germany. [2] Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA. [3] German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kastner</LastName>
            <ForeName>Daniel L</ForeName>
            <Initials>DL</Initials>
            <AffiliationInfo>
              <Affiliation>Inflammatory Disease Section, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mills</LastName>
            <ForeName>Kingston H G</ForeName>
            <Initials>KH</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Masters</LastName>
            <ForeName>Seth L</ForeName>
            <Initials>SL</Initials>
            <Identifier Source="ORCID">000000034763576X</Identifier>
            <AffiliationInfo>
              <Affiliation>The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schroder</LastName>
            <ForeName>Kate</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cooper</LastName>
            <ForeName>Matthew A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Neill</LastName>
            <ForeName>Luke A J</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DK095782</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK091191</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK091191</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL112661</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK095782</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>02</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nat Med</MedlineTA>
        <NlmUniqueID>9502015</NlmUniqueID>
        <ISSNLinking>1078-8956</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005663">Furans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C587672">IL1B protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007192">Indenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C453881">NLRP3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C492716">Nlrp3 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013450">Sulfones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6RS86E2BWQ</RegistryNumber>
          <NameOfSubstance UI="C000597426">N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Nat Rev Rheumatol. 2015 Apr;11(4):198</RefSource>
          <PMID Version="1">25734976</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Nat Rev Immunol. 2015 Apr;15(4):199</RefSource>
          <PMID Version="1">25743221</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Cell Metab. 2015 Apr 7;21(4):513-4</RefSource>
          <PMID Version="1">25863243</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Trends Immunol. 2015 Jun;36(6):323-4</RefSource>
          <PMID Version="1">25991463</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056587" MajorTopicYN="N">Cryopyrin-Associated Periodic Syndromes</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004681" MajorTopicYN="N">Encephalomyelitis, Autoimmune, Experimental</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007192" MajorTopicYN="N">Indenes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013450" MajorTopicYN="N">Sulfones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>1</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25686105</ArticleId>
        <ArticleId IdType="mid">NIHMS676927</ArticleId>
        <ArticleId IdType="pmc">PMC4392179</ArticleId>
        <ArticleId IdType="doi">10.1038/nm.3806</ArticleId>
        <ArticleId IdType="pii">nm.3806</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wen H, Miao EA, Ting JP. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity. 2013;39:432–441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3835203</ArticleId>
            <ArticleId IdType="pubmed">24054327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821–832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20303873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3807999</ArticleId>
            <ArticleId IdType="pubmed">23702978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013–1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24855941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*) Annu Rev Immunol. 2009;27:621–668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2996236</ArticleId>
            <ArticleId IdType="pubmed">19302049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen H, Ting JP. O’Neill, LA A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat Immunol. 2012;13:352–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4090390</ArticleId>
            <ArticleId IdType="pubmed">22430788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Nardo D, De Nardo CM, Latz E. New Insights into Mechanisms Controlling the NLRP3 Inflammasome and Its Role in Lung Disease. Am J Pathol. 2014;184:42–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3873477</ArticleId>
            <ArticleId IdType="pubmed">24183846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol. 2012;57:642–654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22634126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders HJ, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol. 2011;22:1007–1018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21566058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youm YH, et al.  Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 2013;18:519–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4017327</ArticleId>
            <ArticleId IdType="pubmed">24093676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masters SL, et al.  Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-lbeta in type 2 diabetes. Nat Immunol. 2010;11:897–904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3103663</ArticleId>
            <ArticleId IdType="pubmed">20835230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3953875</ArticleId>
            <ArticleId IdType="pubmed">24275598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamkanfi M, et al.  Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009;187:61–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2762099</ArticleId>
            <ArticleId IdType="pubmed">19805629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coll RC, Robertson A, Butler M, Cooper M, O’Neill LA. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PloS one. 2011;6:e29539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3245271</ArticleId>
            <ArticleId IdType="pubmed">22216309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juliana C, et al.  Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010;285:9792–9802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2843228</ArticleId>
            <ArticleId IdType="pubmed">20093358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, et al.  3,4-Methylenedioxy-beta-nitrostyrene Inhibits NLRP3 Inflammasome Activation by Blocking Assembly of the Inflammasome. J Biol Chem. 2014;289:1142–1150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3887181</ArticleId>
            <ArticleId IdType="pubmed">24265316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn H, Kim J, Jeung EB, Lee GS. Dimethyl sulfoxide inhibits NLRP3 inflammasome activation. Immunobiology. 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24380723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perregaux DG, et al.  Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther. 2001;299:187–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11561079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laliberte RE, et al.  Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-lbeta posttranslational processing. J Biol Chem. 2003;278:16567–16578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12624100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariathasan S, et al.  Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440:228–232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16407890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16407889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross O, et al.  Inflammasome activators induce interleukin-lalpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity. 2012;36:388–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22444631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin C, et al.  NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. Proceedings of the National Academy of Sciences of the United States of America. 2011;108:14867–14872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3169126</ArticleId>
            <ArticleId IdType="pubmed">21856950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Netea MG, et al.  Differential requirement for the activation of the inflammasome for processing and release of IL-lbeta in monocytes and macrophages. Blood. 2009;113:2324–2335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2652374</ArticleId>
            <ArticleId IdType="pubmed">19104081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kayagaki N, et al.  Non-canonical inflammasome activation targets caspase-11. Nature. 2011;479:117–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22002608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kayagaki N, et al.  Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science. 2013;341:1246–1249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23887873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broz P, von Moltke J, Jones JW, Vance RE, Monack DM. Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe. 2010;8:471–483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3016200</ArticleId>
            <ArticleId IdType="pubmed">21147462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burckstummer T, et al.  An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol. 2009;10:266–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19158679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hornung V, et al.  AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458:514–518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2726264</ArticleId>
            <ArticleId IdType="pubmed">19158675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009;458:509–513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2862225</ArticleId>
            <ArticleId IdType="pubmed">19158676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts TL, et al.  HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science. 2009;323:1057–1060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19131592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001;8:759–766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11514225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hornung V, et al.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9:847–856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2834784</ArticleId>
            <ArticleId IdType="pubmed">18604214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyden ED, Dietrich WF. Nalplb controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet. 2006;38:240–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16429160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munoz-Planillo R, et al.  K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38:1142–1153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3730833</ArticleId>
            <ArticleId IdType="pubmed">23809161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. The Journal of clinical investigation. 2005;115:2047–2058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1180549</ArticleId>
            <ArticleId IdType="pubmed">16075046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrilli V, et al.  Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell death and differentiation. 2007;14:1583–1589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17599094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horng T. Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome. Trends in immunology. 2014;35:253–261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4041823</ArticleId>
            <ArticleId IdType="pubmed">24646829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Franchi L, Nunez G. TLR agonists stimulate Nlrp3-dependent IL-lbeta production independently of the purinergic P2×7 receptor in dendritic cells and in vivo. Journal of immunology. 2013;190:334–339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3531812</ArticleId>
            <ArticleId IdType="pubmed">23225887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lalor SJ, et al.  Caspase-1-processed cytokines IL-lbeta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. Journal of immunology. 2011;186:5738–5748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21471445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-l in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 2006;203:1685–1691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118338</ArticleId>
            <ArticleId IdType="pubmed">16818675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sutton CE, et al.  Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Thl7 responses and autoimmunity. Immunity. 2009;31:331–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19682929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gris D, et al.  NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Thl and Thl7 responses. Journal of immunology. 2010;185:974–981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3593010</ArticleId>
            <ArticleId IdType="pubmed">20574004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brydges SD, et al.  Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity. 2009;30:875–887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2759865</ArticleId>
            <ArticleId IdType="pubmed">19501000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masters SL, et al.  NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity. 2012;37:1009–1023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4275304</ArticleId>
            <ArticleId IdType="pubmed">23219391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nature genetics. 2001;29:301–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4322000</ArticleId>
            <ArticleId IdType="pubmed">11687797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gattorno M, et al.  Pattern of interleukin-lbeta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007;56:3138–3148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17763411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee GS, et al.  The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature. 2012;492:123–127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4175565</ArticleId>
            <ArticleId IdType="pubmed">23143333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauernfeind F, et al.  Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. Journal of immunology. 2011;187:613–617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3131480</ArticleId>
            <ArticleId IdType="pubmed">21677136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brydges SD, et al.  Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. The Journal of clinical investigation. 2013;123:4695–4705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3809806</ArticleId>
            <ArticleId IdType="pubmed">24084736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Castejon G, Pelegrin P. Current status of inflammasome blockers as antiinflammatory drugs. Expert opinion on investigational drugs. 2012;21:995–1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22612568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fautrel B. Economic benefits of optimizing anchor therapy for rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 4):iv21–iv26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22685272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urban FJ, et al.  Novel synthesis of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea, an anti-inflammatory agent. Synthetic Commun. 2003;33:2029–2043.</Citation>
        </Reference>
        <Reference>
          <Citation>Kuida K, et al.  Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science. 1995;267:2000–2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7535475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, et al.  Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell. 1998;92:501–509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9491891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hett EC, et al.  Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis. Nature chemical biology. 2013;9:398–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6615456</ArticleId>
            <ArticleId IdType="pubmed">23603659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croker DE, et al.  C5a2 can modulate ERK1/2 signaling in macrophages via heteromer formation with C5a1 and beta-arrestin recruitment. Immunology and cell biology. 2014;92:631–639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24777312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sester DP, et al.  A novel flow cytometric method to assess inflammasome formation. Journal of immunology. 2015;194:455–462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25404358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westwell-Roper C, Dunne A, Kim ML, Verchere CB, Masters SL. Activating the NLRP3 inflammasome using the amyloidogenic peptide IAPP. Methods in molecular biology. 2013;1040:9–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23852593</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
